Strategic Intelligence Briefing
This page is a summary of the strategic intelligence BioCreative ran on ZeoScientifiX — and a preview of how that intelligence becomes a clinical-partner database, an engagement system, and a full commercial infrastructure in the Launch program below. Walk it at your pace.
The briefing is yours either way. The page is structured so each section answers one question — what we built, what we found, how it was built, and what comes next.
BioCreative Strategies is an intelligence and infrastructure firm focused on the life sciences. For clinical-stage therapeutic developers we combine multi-agent research with a deterministic life-sciences API stack to deliver clinical, regulatory, partnership, and capital-markets intelligence that is source-traced, auditable, and engineered for the client to own — not rent.
The engagement runs as a build ladder of waves, A through H. This briefing is Wave A. Everything below it is the rest of the ladder.
A continuous, Zeo-tuned news stream — competitive trial readouts, FDA actions, partnership and licensing announcements, financing events, and analyst coverage in your therapeutic and regulatory orbit — collected from a curated set of industry sources, scored by an AI relevance pass against your watchlist, and surfaced in your dashboard. You see only what's relevant to Zeo; we filter the rest.
On-brand drafts for investor updates, scientific communications, partnership outreach, conference materials, and analyst notes — grounded in the same news feed and the same knowledge graph the rest of the system runs on. Brand voice, audience, and angle locked in upfront so drafts feel like a Zeo team member wrote them, not a generic AI.
A Zeo-branded analytics + query layer sitting on top of everything BioCreative builds — knowledge graph, account universe, outbound performance, news intelligence. One pane of glass, live, queryable, exportable. Yours during the engagement and yours after.
Source-traced feeds wired into a single enrichment pipeline. Every signal back-cites the API and the call.
Sponsor, site, PI, status, phase, indication — the live trial graph.
Publication record, co-author graph, preprint signal across every PI in scope.
Active and historical NIH grants, awards by lab and PI.
Federal small-business R&D funding tied to founders and spinouts.
Submissions, approvals, adverse-event signals, label history.
S-1, 10-K, 8-K filings; cap-table, audit, and disclosure history.
Patent assignments and inventor graphs that link academic labs to biotech spinouts.
Title, tenure, institutional moves, intent signal across the investigator, partnership, and analyst graph.
Waterfall enrichment across investigator, partnership, investor, and analyst contact graphs.
BioCreative ran our full intelligence pipeline on ZeoScientifiX and packaged it the same way we deliver for paying clients. Every claim back-cites the dossier and source it came from. Yours either way.
The briefing maps the dual-pathway opportunity: Florida SB 1768 enables immediate state-level commercialization through clinical offices while Phase 2 trials for Zofin continue through the FDA. Each pathway is sized, timed, and source-traced — built for a leadership team to act on, not just read.
If the briefing is useful, the next conversation is a working session. If it isn't, you keep everything we built — no obligation in either direction.
Layer 1 is a positioning framework you can hand to a board observer in 20 minutes. Layer 2 is six domain reports, ~8 pages each. Layer 3 is eight deep-research dossiers, every one cited and source-traced.
SB 1768 (effective July 2025) permits non-FDA-approved stem cell therapies for orthopedics, wound care, and pain management in Florida — but requires cGMP manufacturing. Zeo's FDA-registered Nova Southeastern facility is one of very few that meets the bar. Competitors without compliant manufacturing are locked out. The window closes as federal enforcement posture clarifies or other states legislate — first movers capture the clinic relationships now.
Zofin's EV approach sidesteps the manufacturing complexity and regulatory burden of live-cell products. Only ~15% of the regen-med competitive set operates in the acellular space. This isn't just a technology bet — it's a structural positioning advantage. EVs offer superior scalability, longer shelf life, and simpler logistics, and the FDA's framework for EVs is still crystallizing, creating space for early movers to shape the standards.
Every orthopedic practice, wound care center, and pain management clinic in Florida is a potential Zeo partner under SB 1768. This is a bounded, enumerable target universe. The physician who adopts PPX or Zofin won't switch mid-stream. Building the clinical-office database and executing engagement now, while SB 1768 is new and competitors are still evaluating, locks in relationships that compound over time.
PPX generates revenue today through physician-administered autologous processing. Zofin is the long-term scalable product in Phase 2 trials. Both run through the same cGMP facility. This dual architecture de-risks the company — PPX revenue funds Zofin development, while Zofin's FDA pathway unlocks national and international markets. Shared infrastructure means incremental margin improvement as both lines scale.
Zeo's Physicians Group partnership demonstrates product-channel fit at meaningful volume. But Florida alone has thousands of eligible practices, and national expansion post-FDA would require CDMOs, distribution partners, and institutional relationships at a different scale. The gap between current distribution and addressable market is where a database build and systematic engagement creates the most value.
SB 1768 conflicts with federal FDCA authority. The FDA hasn't signaled enforcement posture yet, but precedent (US v. Regenerative Sciences, 2014) shows the agency acts against non-compliant operators. Zeo's FDA-registered cGMP facility is the strongest available defense. If enforcement comes, it targets non-compliant operators first — potentially strengthening Zeo's position by eliminating under-invested competitors.
The same AI engineering principles Zeo applies to regenerative biologics manufacturing and dual-pathway clinical commercialization — APIs at every layer, audit trails end-to-end, deterministic outputs, source traceability — applied to the clinical, regulatory, and partnership intelligence layer. Multi-tenant where it should be, single-tenant where it has to be. The same pipeline that produced this briefing is the one that powers everything below.
Parallel agents fan out across leadership, market, competitive, regulatory, financial, technology, commercial, and customer-base dimensions. Each agent is scoped, source-traced, and rate-limited so the briefing is reproducible, not improvised.
Stack: Custom multi-agent framework on Anthropic Claude + OpenAI + Google Gemini, orchestrated through our Brain layerAgent traces are folded into domain reports by a long-context model that pressure-tests claims, surfaces contradictions, and back-cites every line.
Stack: Gemini 2.x for long-context synthesis · Claude Sonnet for refinement & judgingWe map the live graph of clinical investigators, partnership prospects, analysts, and investors around each prospect — the actual people, titles, institutions, and signals that make up the engagement universe — before any outreach is written. Already started for Zeo's orbit.
Stack: LinkedIn Sales Navigator · Clay enrichment · BioCreative's life-sciences contacts databaseDeterministic data feeds — clinical trials, biomedical literature, grant funding, FDA submissions, SEC filings, patent activity — pulled into the same enrichment pipeline.
Stack: ClinicalTrials.gov · PubMed · NIH RePORTER · FDA · SEC EDGAR · USPTO patent feedsYour brand language, palette, typography, and product taxonomy scraped and applied so deliverables feel native. This page is itself the example — Zeo primary #ED4B00 and dark #020035 lifted directly from zeoscientifix.com.
Every claim cites the dossier and source it came from. Every artifact — code, data, prompts, dashboards — is yours to own at handoff of any engagement. No model lock-in, no infrastructure lock-in.
Stack: Postgres / Supabase data layer · documented APIs · transferable IPWe map every SB 1768–eligible clinical practice in Florida — orthopedics, wound care, pain management, regenerative medicine — layer physician profiles, practice volume signals, existing regen-med adoption markers, and regulatory eligibility on top, and deliver a fit-scored, contact-ready database. The point: reach the right physician at 'considering regenerative options,' not 'already committed to a competitor's product.'
Stack: LinkedIn Sales Navigator · Clay enrichment · BioCreative life-sciences contacts database · Florida medical licensing data · practice-level classification agentsEvery orthopedic practice, wound care center, pain management clinic, and regenerative medicine provider in Florida is now a potential Zeo partner. Run our pipeline on Zeo's clinical and therapeutic adjacencies and you get a purpose-built, contact-attached, fit-scored database of the physicians and practice managers most likely to adopt PPX or participate in Zofin clinical programs — plus the regulatory context that makes each office SB 1768-eligible.
It would be unusual for a clinical-stage company to have this kind of physician-office intelligence before building a commercial team. We'd build it for Zeo inside the Launch program below. Approximate scope after specialty and regulatory filtering:
Wave A is done — that's the briefing on this page. Waves B through H are the build ladder that sits on top of it. Same AI engineering principles Zeo's product is built on — APIs at every layer, audit trails end-to-end, deterministic outputs, full source traceability. Multi-tenant where it should be, single-tenant where it has to be. Every artifact owned by Zeo at handoff.
Objective: Capture the strategy and decisions that everything downstream reads from. Working sessions with the Zeo leadership team, document sharing, structured decisions on therapeutic priorities, regulatory posture, partnership architecture, and investor / analyst communication voice.
Delivered: Alignment doc, strategy log, priority queue, voice and messaging guidelines, structured intake of internal artifacts.
You keep: Every working-session artifact, the strategy log, the alignment doc.
Stack: Structured intake workflow · shared doc workspace
Objective: Combine BioCreative's research assets with Zeo's therapeutic focus areas, pipeline assets, and regulatory posture into a queryable, client-private knowledge graph and the foundational database the rest of the waves run against.
Delivered: Versioned knowledge graph (Postgres-backed), seed data, semantic search layer, and the first wiring of the personalized live newsfeed described above.
You keep: Schema, graph, query layer, refresh runbooks.
Stack: Postgres / Supabase · semantic search · BioCreative life-sciences API layer
Objective: Find, verify, enrich, and structure every clinical investigator, partnership prospect, analyst, and investor in Zeo's engagement universe.
Delivered: Enriched investigator + partnership + analyst universe (institutional affiliations, trial track record, publication graph, partnership history, coverage history), per-contact records with email + LinkedIn coverage, intent + trigger detection (new trials, FDA filings, fundraises, executive hires), and the investigator and partnership database from the callout above.
You keep: Full database export, query layer, refresh runbooks, every API key transferred to Zeo-controlled accounts at handoff.
Stack: Clay (waterfall enrichment) · LinkedIn Sales Navigator · ClinicalTrials.gov · PubMed · bioRxiv/medRxiv · NIH RePORTER · SBIR/STTR · Drugs@FDA + openFDA · SEC EDGAR · USPTO · custom intent agents
Objective: Translate the joined Wave A + B + C + D picture into deterministic investigator-fit, partnership-fit, and analyst-coverage models across Zeo's therapeutic and capital-markets surface area.
Delivered: Versioned persona schemas, classification rules, fit-scoring models, and engagement-universe sizing tied directly to the live database.
You keep: Schema definitions, classification logic, scoring code, full audit log of inputs.
Stack: Postgres / Supabase · custom classification agents · scoring service
Objective: Stand up a multi-channel investigator and partnership engagement motion driven by an AI messaging agent that composes per-investigator, per-partner, per-analyst communications grounded in the full enrichment record — and ship measured engagement.
Delivered: Warmed email infrastructure, live LinkedIn motion, AI messaging agent with prompt + model + guardrails versioned in code, conversation classifier, dashboards.
You keep: Domain ownership, mailbox ownership, agent code + prompts, dashboards, reply data, every workflow.
Stack: EmailBison · HeyReach · custom messaging agent (Claude / Gemini / OpenAI) · reply classifier · Postgres dashboard layer
Objective: Close the loop on the engagement motion. Every inbound reply, form fill, and warm intent signal classified, routed, and (where appropriate) replied to by an AI agent grounded in the same knowledge graph as outbound.
Delivered: Inbound classifier (clinical interest / partnership inquiry / analyst question / investor relations / book-a-meeting), routing rules to the right Zeo owner, an AI reply agent for first-touch follow-ups with human-in-the-loop review, calendar handoff, full conversation memory.
You keep: Classifier code, routing logic, agent prompts, conversation history.
Stack: Reply classifier · AI inbound agent · calendar + CRM integrations · conversation store
Objective: Keep the system sharp. Therapeutic landscapes drift, the regulatory environment drifts, the partnership and analyst graph drifts. Wave H is the cadence — model tuning, prompt revisions, database refreshes, dashboards reviewed against engagement reality.
Delivered: Quarterly tune-ups, regression testing on the agent stack, refreshed enrichment passes, new trigger types as the landscape evolves, joint engagement reviews with the Zeo clinical and partnership leadership.
You keep: Everything we built. Wave H is optional, scoped on what you actually want to keep us close on.
Note: Zeo-specific accounts (sending domains, mailbox seats, Clay seat, HeyReach workspace) sit on Zeo infrastructure. BioCreative's firm-wide tooling (master Sales Navigator seat, master Clay workspace) stays with us — same model any build engagement uses.
Code, data, prompts, dashboards, infrastructure — all transferred to Zeo at handoff. We don't run an "AI black box" you keep paying us to operate. Launch is a build engagement; what we hand back is yours, the same way Zeo hands clinicians and partners a real, defensible therapeutic platform.
The briefing above is the intelligence layer. Below is the execution layer — the same AI-empowered back-end, the same operator, extended to cover every orthopedic practice, wound care center, pain management clinic, and regenerative medicine provider in Florida. Turn-key, measured, and yours to own.
We build a custom database of every orthopedic practice, wound care center, pain management clinic, and regenerative medicine provider in Florida in Florida — not a list purchase, a purpose-built intelligence asset.
Every record enriched with full contact data (email, phone, LinkedIn), institutional context, and scored against your Ideal Clinical Profile criteria. The same enrichment stack (Sales Navigator, Clay, PhantomBuster, BioCreative classification agents) that powers every BioCreative engagement, configured specifically for Zeo.
Not just intelligence — execution across every channel that matters for Zeo.
AI-powered messaging grounded in the same knowledge graph and enrichment data. Per-recipient personalization, A/B testing, reply classification, and conversation memory — all managed from one system.
AI-powered messaging grounded in the same knowledge graph and enrichment data. Per-recipient personalization, A/B testing, reply classification, and conversation memory — all managed from one system.
AI-powered messaging grounded in the same knowledge graph and enrichment data. Per-recipient personalization, A/B testing, reply classification, and conversation memory — all managed from one system.
AI-powered messaging grounded in the same knowledge graph and enrichment data. Per-recipient personalization, A/B testing, reply classification, and conversation memory — all managed from one system.
Build scientific credibility across every digital channel — from peer-reviewed content to conference presence to investor communications — powered by the same AI back-end that produced this briefing.
9 channels (LinkedIn personal/company, X, Instagram, Threads, Bluesky, blog, newsletter, Moltbook), 14 content types, channel-specific personas. Brand Voice Guardian + Quality Scoring layers run on every output before it ships. Your thought leadership — repurposed and scheduled across every channel automatically.
Five-tab dashboard plugged into Google Analytics 4, Google Search Console, and AI citation tracking. Every published asset scored, keyworded, and position-tracked. Entity analysis for search intent. Color-coded ranking badges. Continuous optimization so Zeo lands at the top — in traditional search and in AI-generated answers.
Investor updates, scientific communications, conference materials, partnership outreach, analyst notes — grounded in the same knowledge graph the rest of the system runs on. Brand voice, audience, and angle locked in so every piece reads like a Zeo team member wrote it.
Cross-platform scheduling, brand-consistent content creation, engagement monitoring, and performance analytics. Every post aligned to Zeo's messaging guidelines and therapeutic positioning. Community management and audience development included.
Intelligence + database + engagement + marketing — all running on the same AI-empowered back-end. One knowledge graph, one brand voice, one set of dashboards, one team. The same standardized commercial systems that power the Launch program, extended to cover everything Zeo needs to reach Florida.
Everything on this page is yours either way. If we end up working together, what we hand back is yours too — code, data, prompts, dashboards, infrastructure, all of it.
— Brian Allen, BioCreative Strategies
brian@biocreativestrategies.com